BSEBoard Meeting5d ago · 13 Nov 2026, 02:13 pm
Outcome of Board Meeting
Natco Pharma Ltd · 524816
✦ AI Summary▲ PositiveResults
Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a second interim dividend of Rs. 1.25 per equity share. The company has also provided a consolidated balance sheet as of September 30, 2026.
Analysis Scores
Earnings Impact8/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
Attachments (1)
📄pdf
Download →
dbcf6652-318c-4a45-85fb-b62b9905fd6f.pdf
View document text
November 13, 2026
Corporate Relationship Department The Manager – Listing
M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd.
Mumbai – 400 001. Mumbai – 400 051.
Scrip Code: 524816 Scrip Code: NATCOPHARM
Dear Sir/Madam,
Sub: Outcome of Board Meeting
We would like to inform you that the Board of Directors of the Company at their meeting held today have
considered and approved the following along with other items of business:
1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended
September 30, 2026 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33
of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015 as amended from time to time (“Listing Regulations”) along with Limited Review
Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your
information.
2. Declared second interim dividend of Rs. 1.25 (Rupees one rupee twenty five paise only) ( 62.50%) each
per equity share of Rs.2/- (Rupees two only) each for the financial year 2026-27. The date for taking
on record of its shareholders eligible for the purpose of payment of second interim dividend i.e., record
date is fixed as Thursday, the 19th day of November 2026. The payment of said interim dividend will
start from November 27, 2026.
A Copy of Press release is also enclosed for your information.
Meeting commenced at 11:50 a.m. and concluded at 2:00 p.m.
Thanking you
Yours faithfully,
For NATCO Pharma Limited
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer
Encl: As above
NATCO Pharma Limited
Regd. Office: Natco House, Road No. 2,Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-23547532, Website : www.natcopharma.co.in, CIN: L2423OTG1981PLC003201
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09-2026
in millions except per share
Quarter ended Half year ended Year ended
S.No Particulars 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026
Unaudited Unaudited Unaudited Unaudited Unaudited Audited
Ilncome
1 ln"r"nr" from operations 9,673 7,352 13,630 17,025 26,919 40,783
2 lOther income 521 592 1,000 1,113 1,617 2,976
3 lTotal income (t+z) 10,194 7,9M 't4,630 18,138 28,536 43,7s9
| =ro"n="=
lCost of materials consumed 1,717 1,578 1,749 3,295 3,555 5,935
I Purchases of stock-in-trade 818 278 726 1,096 1,099 2,032
lC stoh c" kn -g in" -" t rain d einventories of finished goods, work-in-progress and (704) (s81 ) (778) (1,085) (627) (1,062)
lemptoy"e benefits expense 2,036 1,793 2,003 3,829 3,693 6,872
I Finance cosls 176 130 131 306 163 367
lDepreciation, amortisation and impairment expenses 492 471 524 963 1,100 2,066
expenses 3,227 2,219 4,138 5,446 7,697 12,641
lOther
expenses 7,762 6,06E 8,493 1 3,850 1 6,680 28,85',1
lTotal
5 Profit before tax and share of profit of associate (3-4) 2,432 1,856 6,137 4,288 1 1,856 14,908
6 I Tax expense
(i) Current tax 436 488 1,404 924 2,561 3,035
(ii) Deferred tax (refer note 7) 262 146 (446 408 (6871 (1,846
Total tax expense 698 634 9s8 1,332 1,874 't,189
7 Profit for the period/ year before share of profit of associate (5-6) 1,734 1,222 5,1_79 2,956 9,982 13,719
8 Share of profit of associate (net of tax) 292 843 1,135 466
I Profit for the period/ year (7+8) 2,026 2,065 5,179 4,091 9,982 14,185
10 Other comprehensive income/ (loss) ('OCl') (net of tax)
(i), ltems that will not be reclassified to profit or loss:
Remeasurement of defined benefit liability/(asset) 1 1 1 1 19
Tax on remeasurement of defined benefit liability/(asset) (7)
Fair value changes of Equity investments through OCI 12 103 184 115 237 478
Tax impact on Fair value changes on Equity investments through OCI (1 (1 5) (37 (16) (44 (87)
11 89 148 100 194 403
(ii). ltems that will be reclassified to profit or loss:
Exchange differences on translating financial statements of foreign 498 1,088 256 1,586 603 2,518
operations
Share of OCI of associate (net of tax) G t6t (71', (47
494 1,021 256 1,s1s 603 2,471
Other comprehensive income for the period/ year, net of tax 505 1 110 404 1,615 797 2,874
11 Total comprehensive income for the period/ year (9+10) 2,531 3,175 5,583 5,706 10,779 1 7,059
12 Profit for the period/year attributable to:
Owners of the Company 2,0_26 2 065 5,184 4,0-91 9,991 14,1_85
Non-controlling interests (51 (el
13 Other comprehensive income for the period/ year attributable to:
Owners of the Company 505 1,1_10 4-04 1,615 7-97 2,8_74
Non-controlling interests
14 Total comprehensive income for the period/ year attributable to:
Owners of the Company 2,5-31 3,1_75 5,588 5,706 1 0,788 17,059
Non-controlling interests (5) (s)
15 Paid-up equity share capital (Face value of ti each) 358 358 358 358 358 358
16 Other equity 91,E53
17 Earnings per share (not annualised for the quarters)
(Face value of t2 each)
Basic (in {) 11 .31 '1 1.53 28.94 22.84 55.78 79.20
Diluted (in t) 11.31 11.53 28.94 22.84 55.78 79.20
See accompanying notes to lhe unaudited consolidated financial resrults
NATCO Pharma Limited
Consolidated Balance Sheet:
Assets
(1) Non-current assets
(a) Property, plant and equipment
(b) Capital work-in-progress 25,963 25,454
(c) Goodwiil 3,961 2,937
(d) Other intangible assets 644 630
(e) lnvestments accounted for using equity method 1,850 1,943
(f) Financial assets 35,034 22,757
lnvestments
(ii) Other financial assets 4,652 2,732
(g) Deferred tax assets, net 3'10 620
(h) Non-current tax assets, net 1,946 2,326
(i) Other non-current assets 129 116
Total non-current assets 699
(2) Gurrent assets
(a) Inventories
(b) Financial assets 10,062 9,085
lnvestments
(ii) Trade receivables 4,483 5,782
(iii) Cash and cash equivalents 8,034 8,812
(iv) Bank balances other than (iii) above 1,385 't,989
(v) Loans 9,305 13,520
't06
(vi) Other financial assets 98
(c) Other current assets 4,502 7,418
Total current assets 3,819
Total assets
EQUITYAND LIABILITIES
(1) Equity
(a) Equity share capital
(b) Other equity
Equity attributable to owners of the Company
(c) Non-controlling interest
Total equity
(2) Liabilities
(A) Non-current liabilities
(a) Financiat liabilities
(i) Borrowings
(ia) Lease liabilities
(ii) Other financial liabilities
(b) Provisions
(c) Deferred tax liabilities (net)
Total non-current liabilities
(B) Current liabilities
(a) Financial liabilities
(i) Borrowings
(ia) Lease liabilities 6,064
(ii) Trade payables 33
- Totar outstanding dues of micro enterprises and smail enterprises; and 278
-T so mta ar l l o eu nts teta rpn rd isin eg s dues of creditors other than micro enterprises and 3,815
(iii) Other financial liabilities
(b) Other current liabilities 1,381
(c) Provisions 1,731
(d) Current tax tiabitities (net) 3,502
Total current liabilities 5
Total liabilities
Total equity and liabilities
NATCO Pharma Limited
Consolidated Statement of Cash Flows:
Half year ended
30-09-2026 30-09-2025
(Uanudited) (Uanudited)
flows from operating activities
before tax for the year
for 1 1,856
amortisation and impairment expenses
Finance costs 963 't ,1 00
306 163
lnterest income
(e1 e) (1,274)
for impairment of receivables and advances, net
50 't2
debts written off
Loss/ (gain) on sale / discard of property, plant and equipment
)/ loss on sale of investments
income on equity investment at fair varue through other comprehensive income (2)
rd foreign exchange gain, net
profit before working capital changes
4,67i
in working capital:
' (increase) in inventories
(977
(increase) in trade receivables
(increase) in other financial assets
t (14)
(increase) in other assets
(665 (131)
lncrease/ (decrease) in trade payables
151 2,375
lncrease/ (decrease) in provislons
(decrease) in other financial liabilities (2,1se 3,496
rse/ (decrease) in other liabilities 29e 661
(20.'
generated from operating activities 72',\
paid, net of refund 2,041 13,90'
cash generated from operating activitibs (A) (398 (1.995
flows from investing activities
Purchase of property, plant and equipmen
[Showing first 8,000 characters — download PDF for full document]